Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Venous thromboembolism clinically detected after hip fracture surgery with prophylaxis in a clinical practice setting.

Comp P, Happe LE, Sarnes M, Farrelly E.

Am J Orthop (Belle Mead NJ). 2008 Sep;37(9):470-5.

PMID:
18982184
2.

Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis.

Shorr AF, Kwong LM, Sarnes M, Happe L, Farrelly E, Mody-Patel N.

Thromb Res. 2007;121(1):17-24. Epub 2007 Apr 20.

PMID:
17449088
3.

Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.

Shorr AF, Sarnes MW, Peeples PJ, Stanford RH, Happe LE, Farrelly E.

Am J Health Syst Pharm. 2007 Nov 15;64(22):2349-55.

PMID:
17989444
4.

Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study.

Migita K, Bito S, Nakamura M, Miyata S, Saito M, Kakizaki H, Nakayama Y, Matsusita T, Furuichi I, Sasazaki Y, Tanaka T, Yoshida M, Kaneko H, Abe I, Mine T, Ihara K, Kuratsu S, Saisho K, Miyahara H, Segata T, Nakagawa Y, Kamei M, Torigoshi T, Motokawa S.

Arthritis Res Ther. 2014 Jul 21;16(4):R154. doi: 10.1186/ar4616.

5.

Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis.

Schiff RL, Kahn SR, Shrier I, Strulovitch C, Hammouda W, Cohen E, Zukor D.

Chest. 2005 Nov;128(5):3364-71.

PMID:
16304285
6.

Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.

Donath L, Lützner J, Werth S, Kuhlisch E, Hartmann A, Günther KP, Weiss N, Beyer-Westendorf J.

Br J Clin Pharmacol. 2012 Dec;74(6):947-58. doi: 10.1111/j.1365-2125.2012.04302.x.

7.

Comparison of injectable anticoagulants for thromboprophylaxis after cancer-related surgery.

Changolkar A, Menditto L, Shah M, Puto K, Farrelly E.

Am J Health Syst Pharm. 2014 Apr 1;71(7):562-9. doi: 10.2146/ajhp120711.

PMID:
24644116
8.

Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries.

Happe LE, Farrelly EM, Stanford RH, Sarnes MW.

J Thromb Thrombolysis. 2008 Oct;26(2):125-31. Epub 2007 Nov 24.

PMID:
18034323
9.
11.

Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.

Annemans L, Minjoulat-Rey MC, De Knock M, Vranckx K, Czarka M, Gabriel S, Haentjens P.

Acta Clin Belg. 2004 Nov-Dec;59(6):346-57.

PMID:
15819379
12.

Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.

Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS.

Clin Ther. 2007 Nov;29(11):2395-405. Review.

PMID:
18158080
13.

The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.

Gordois A, Posnett J, Borris L, Bossuyt P, Jönsson B, Levy E, de Pouvourville G.

J Thromb Haemost. 2003 Oct;1(10):2167-74.

14.

Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.

Droege ME, Mueller EW, Besl KM, Lemmink JA, Kramer EA, Athota KP, Droege CA, Ernst NE, Keegan SP, Lutomski DM, Hanseman DJ, Robinson BR.

J Trauma Acute Care Surg. 2014 Feb;76(2):450-6. doi: 10.1097/TA.0000000000000087.

PMID:
24458050
15.

Early venous thromboembolic event prophylaxis in traumatic brain injury with low-molecular-weight heparin: risks and benefits.

Dudley RR, Aziz I, Bonnici A, Saluja RS, Lamoureux J, Kalmovitch B, Gursahaney A, Razek T, Maleki M, Marcoux J.

J Neurotrauma. 2010 Dec;27(12):2165-72. doi: 10.1089/neu.2010.1366.

PMID:
20939698
16.
17.
18.

A retrospective analysis of the effectiveness of low molecular weight heparin for venous thromboembolism prophylaxis in trauma patients.

Gritsiouk Y, Hegsted DA, Schlesinger P, Gardiner SK, Gubler KD.

Am J Surg. 2014 May;207(5):648-51; discussion 651-2. doi: 10.1016/j.amjsurg.2013.12.010. Epub 2014 Jan 30.

PMID:
24560359
19.

Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery.

Farias-Eisner R, Horblyuk R, Franklin M, Lunacsek OE, Happe LE.

Curr Med Res Opin. 2009 May;25(5):1081-7. doi: 10.1185/03007990902837117 .

PMID:
19298219
20.

Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.

Turpie AG.

Surg Technol Int. 2004;13:261-7. Review.

PMID:
15744699

Supplemental Content

Support Center